BPC-157 Arginate (Oral)
BPC-157 Arginate is a salt form of BPC-157 combined with arginine to improve stability in the gastrointestinal tract, enabling oral administration in place of subcutaneous injection. The rationale is that the arginate salt resists gastric acid degradation better than the standard peptide, though head-to-head human bioavailability comparisons have not been published. Preclinical GI evidence for BPC-157 broadly supports oral efficacy for gut-specific endpoints such as ulcer protection and colitis, where local rather than systemic exposure may be sufficient. No human clinical trials have been conducted on the arginate formulation specifically; it shares the same unregulated research compound status as standard injectable BPC-157.
Evidence last reviewed: 04 Apr 2026
Not a routine supplement — not recommended for self-directed use.
Information here is educational only, not a recommendation to use. See our Safety page.
Verify this peptide on CertiPep
certipep.ch — anonymous purity & characterization service
Evidence is from research or clinical settings — does not imply safety outside supervised contexts.
The evidence for BPC-157 primarily comes from animal studies and mechanistic research, indicating potential benefits for gastrointestinal issues. However, there are significant gaps in human clinical trials, particularly for the arginate formulation.
GI mucosal protection (general BPC-157 literature)Mostly animal/in vitro · Mechanistic/animal (inference)Very low
BPC-157 has preclinical GI model literature; this does not validate a specific marketed oral formulation in humans.